Drug Trial Radar · NCT04865770
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Apr 28, 2021
Primary completion
Nov 21, 2024
Study completion Nov 21, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys. Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance. Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week. The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations. Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours. The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.
Conditions
- Diabetes Mellitus, Type 2
- Chronic Kidney Disease
Interventions
SemaglutideDrug
Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Placebo (Semaglutide)Drug
Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)Time frame: Baseline (week 0), End of treatment (week 52)
- Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)Time frame: Baseline (week 0), End of treatment (week 52)
- Change in Global Kidney Perfusion (MRI)Time frame: Baseline (week 0), End of treatment (week 52)
- Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)Time frame: Baseline (week 0), End of treatment (week 52)
- Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)Time frame: Baseline (week 0), End of treatment (week 52)
Locations
49 sites in 8 countries. Site status is shown where the registry gives one.
University of Arizona-CaTs
Tucson, Arizona
Academic Medical Research Institute
Los Angeles, California
Roderick A. Comunale II MD Inc.
National City, California
N America Res Inst - San Dimas
San Dimas, California
UC Anschutz Medical Campus
Aurora, Colorado
Advent Health-Res Inst
Orlando, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
Emory University Hsptl - Atlanta
Atlanta, Georgia
Endeavor Health Glenbook Hosp
Evanston, Illinois
North Suburban Nephrology LLC
Gurnee, Illinois
University of Minnesota Health Clinical
Minneapolis, Minnesota
Clinical Research Consultants, LLC
Kansas City, Missouri
Cleveland Clinic_Cleveland
Cleveland, Ohio
Prolato Clinical Research Cntr
Houston, Texas
Sun Research Institute
San Antonio, Texas
NE Clin Res of San Antonio
San Antonio, Texas
University of Texas San Antonio
San Antonio, Texas
Univ of Washington Med Ctr
Seattle, Washington
Providence Medical Research Center
Spokane, Washington
Medical College Of Wisconsin
Milwaukee, Wisconsin
LMC ClinRsrh Inc.Brampton
Brampton, Ontario, Canada
UHN-Toronto General Hospital
Toronto, Ontario, Canada
Nefrologisk Klinik P 2132
Copenhagen, Denmark
Rigshospitalet - Nefrologisk Klinik P 2132
Copenhagen, Denmark
Steno Diabetes Center Copenhagen
Herlev, Denmark
Centre Hospitalier Universitaire Amiens Picardie-Site Sud
Amiens, France
Centre Hospitalier Universitaire de Rouen - Hopital de Bois Guillaume
Bois-Guillaume, France
Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2
Grenoble - Cédex 09, France
Les Hopitaux de Chartres-Hopital Louis Pasteur
Le Coudray, France
Chu de Reims-Hopital Maison Blanche
Reims, France
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
Toulouse, France
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Italy
Azienda Ospedaliera di Padova Clin.Med.3
Padova, Italy
Presidio Ospedaliero Cisanello
Pisa, Italy
Azienda Ospedaliero - Universitaria Sant'Andrea
Roma, Italy
Istituto Scientifico San Raffaele
Milan, MI, Italy
In-Vivo Sp. z o.o.
Bydgoszcz, Poland
Centrum Medyczne "Diabetika"
Radom, Poland
Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie
Szczecin, Poland
Miedzyleski Szpital Specjalistyczny, Oddzial Nefrologiczny
Warsaw, Poland
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.